Original Article

LUCAT1 Activates the Malignant Phenotypes of Lung Cancer Cells via Regulating P53 Ubiquitination

Abstract

Background: Long non-coding RN (lncRNAs) have been implicated in lung cancer, but the mechanisms stay unclear. We investigated the theatrical role and mechanism of lncRNA Lung cancer associated transcript 1 LUCAT1 in the malignant progress of lung cancer.
Methods: From May 2022 to March 2023, a total of thirty normal and cancerous tissues were collected from patients diagnosed with non-small cell lung cancer at Zhongke Gengjiu Hospital in Anhui Province, China. The human SPC-A1 and A549 cell lines were chosen as the subjects for the relevant cellular experiments in this study. LncRNAs were expressed in a different manner identified by bioinformatics methods, and the expression levels in lung cancer tissues as well as cells were verified by the qRT-PCR assay. The biological role of LUCAT1 in NSCLC was determined by CCK-8, EdU, and transwell assay.
Results: The regulation of ubiquitin of P53 by LUCAT1 was studied, which showed that LUCAT1 was significantly elevated in NSCLC cell lines and patients’ tissues (P<0.05). High levels of LUCAT1 promoted the proliferation, invasion, and migration of NSCLC cells. Mechanism studies showed that LUCAT1 was mainly located in the nucleus, which bound to P53 and mediated the ubiquitinated degradation of P53. Meanwhile, LUCAT1 knockdown attenuated the ubiquitination process of P53. In addition, rescue experiments illustrated that LUCAT1 induced the proliferation and invasion of NSCLC cells, and played a key role in the survival and tumorigenicity of NSCLC cells by mediating the ubiquitination of P53.
Conclusion: Collectively, LUCAT1 activated the malignant phenotypes of NSCLC cells via regulating P53 ubiquitination, which provided a new idea for the diagnosis and treatment of NSCLC.

1. Iyer MK, Niknafs YS, Malik R, et al (2015). The landscape of long noncoding RNAs in the human transcriptome. Nat Genet, 47(3): 199-208.
2. Schmitt AM, Chang HY (2016). Long Noncoding RNAs in Cancer Pathways. Cancer Cell, 29(4): 452-463.
3. Arun G, Diermeier SD, Spector DL (2018). Therapeutic Targeting of Long Non-Coding RNAs in Cancer. Trends Mol Med, 24(3): 257-277.
4. Niknafs YS, Han S, Ma T, Speers C, et al (2016). The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. Nat Commun, 7: 12791.
5. Malik R, Patel L, Prensner JR, et al (2014). The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer. Mol Cancer Res, 12(8): 1081-7.
6. Statello L, Guo CJ, Chen LL, Huarte M (2021). Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol, 22(2): 96-118.
7. Feretzaki M, Pospisilova M, Valador Fernandes R, Lunardi T, Krejci L, Lingner J (2020). RAD51-dependent recruitment of TERRA lncRNA to telomeres through R-loops. Nature, 587(7833): 303-308.
8. Slack FJ, Chinnaiyan AM (2019). The Role of Non-coding RNAs in Oncology. Cell, 179(5): 1033-1055.
9. Li G, Kryczek I, Nam J, et al (2021). LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy. Nat Cell Biol, 23(5): 526-537.
10. Kandoth C, McLellan MD, Vandin F, et al (2013). Mutational landscape and significance across 12 major cancer types. Nature, 502(7471): 333-339.
11. Chen J (2016). The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression. Cold Spring Harb Perspect Med, 6(3): a026104.
12. Mantovani F, Collavin L, Del Sal G (2019). Mutant p53 as a guardian of the cancer cell. Cell Death Differ, 26(2): 199-212.
13. Shin YJ, Kim Y, Wen X, Cho NY, Lee S, Kim WH, Kang GH (2019). Prognostic implications and interaction of L1 methylation and p53 expression statuses in advanced gastric cancer. Clin Epigenetics, 11(1): 77.
14. Dai C, Gu W (2010). p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med, 16(11): 528-36.
15. Pant V, Lozano G (2014). Limiting the power of p53 through the ubiquitin proteasome pathway. Genes Dev, 28(16): 1739-51.
16. Thai P, Statt S, Chen CH, Liang E, Campbell C, Wu R (2013). Characterization of a novel long noncoding RNA, SCAL1, induced by cigarette smoke and elevated in lung cancer cell lines. Am J Respir Cell Mol Biol, 49(2): 204-11.
17. Sun Y, Jin SD, Zhu Q, et al (2017). Long non-coding RNA LUCAT1 is associated with poor prognosis in human non-small lung cancer and regulates cell proliferation via epigenetically repressing p21 and p57 expression. Oncotarget, 8(17): 28297-28311.
18. Chen Y, Yu X, Xu Y, Shen H (2017). Identification of dysregulated lncRNAs profiling and metastasis-associated lncRNAs in colorectal cancer by genome-wide analysis. Cancer Med, 6(10): 2321-2330.
19. Zheng ZG, Xu H, Suo SS, et al (2016). The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer. Sci Rep, 6: 26093.
20. Wen Y, Wu J, Pu Q, et al (2023). ABT-263 exerts a protective effect on upper urinary tract damage by alleviating neurogenic bladder fibrosis. Ren Fail, 45(1): 2194440.
21. Dey BK, Mueller AC, Dutta A (2014). Long non-coding RNAs as emerging regulators of differentiation, development, and disease. Transcription, 5(4): e944014.
22. Zhang K, Shi H, Xi H, et al (2017). Genome-Wide lncRNA Microarray Profiling Identifies Novel Circulating lncRNAs for Detection of Gastric Cancer. Theranostics, 7(1): 213-227.
23. Fattahi S, Kosari-Monfared M, et al (2020). LncRNAs as potential diagnostic and prognostic biomarkers in gastric cancer: A novel approach to personalized medicine. J Cell Physiol, 235(4): 3189-3206.
24. Wang L, Shao X, Zhong T, et al (2021). Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy. Nat Chem Biol, 17(5): 567-575.
25. Patnaik A, Rosen LS, Tolaney SM, et al (2016). Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. Cancer Discov, 6(7): 740-53.
26. Fassl A, Brain C, Abu-Remaileh M, et al (2020). Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition. Sci Adv, 6(25): eabb2210.
27. Kumarasamy V, Vail P, Nambiar R, Witkiewicz AK, Knudsen ES (2021). Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition. Cancer Res, 81(5): 1347-1360.
28. Green DR, Kroemer G (2009). Cytoplasmic functions of the tumour suppressor p53. Nature, 458(7242): 1127-30.
Files
IssueVol 53 No 9 (2024) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijph.v53i9.16458
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Zhang J, Gong W, Wang X, Yang L. LUCAT1 Activates the Malignant Phenotypes of Lung Cancer Cells via Regulating P53 Ubiquitination. Iran J Public Health. 2024;53(9):2049-2058.